We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Expert: European Council Likely to Release Device Regs in June

Expert: European Council Likely to Release Device Regs in June

May 15, 2015

Devicemakers should expect to see the European Council’s final version of the proposed medical device and in vitro medical device regulations next month, an EU industry official says.

John Brennan, director of regulations and industrial policy at MedTech Europe, says there’s a 90 percent chance the Council will wrap up its three years of confidential talks and sign off on the proposal next month. If that happens, the proposal would go to the health minister on June 19.

Once the health minister has the two documents, the European Parliament, Council and the European Commission will work to finalize the regulations. Each body has created its own draft and the Council’s is the last to be released. Brennan, who provided the update at MedCon 2015 in Cincinnati, Ohio, expects the regulations to be enacted in the first half of 2016.

The negotiations have been tricky because each of the EU’s 28 member states must agree to implement the regulations to the letter of the law, Brennan says. Previously, countries could tweak EU recommendations on device regulation to fit local conditions.

Key changes include increased traceability requirements, better central control over notified bodies and a stricter approach to hazardous materials used in devices. The proposed regulations would impose an immediate four-year ban on any manufacturer found to use hazardous substances, but Brennan says that will be stepped down to a sensible and science-based approach the industry would support.

Changes to IVD regulations, including requests for clinical evidence that rise to near-pharma level, may cause the most challenge, Brennan says. “The whole IVD discussion is being overshadowed by the device discussion.”

Another concern, he says, is that the current versions of the regulations don’t properly differentiate requirements that would be imposed on Class III devices from requirements for all devices. That could lead to problems if the stricter standards are imposed sector-wide, Brennan says.

Industry would also like to see more forward motion on unique device identifiers throughout Europe, Brennan says. The concept of using UDIs to build a centralized database is widely supported, but has been stymied by inaction at all levels, he says. — Elizabeth Orr

Regulatory Affairs

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • WhiteHouse.gif

    President Biden Issues Executive Order on U.S. Supply Chain

  • roche.gif

    Priority Healthcare Settles Diabetes Test Lawsuit with Roche for $43 Million

  • Effective text

    Pfizer/BioNTech Vaccine Equally Effective for All Age Groups, Israeli Study Says

  • Siemens Healthineers logo

    Siemens Healthineers’ COVID-19 Antigen Lab Test Receives CE Mark

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing